Issue Date: December 18, 2017
Teva will cut 14,000 jobs worldwide
Kåre Schultz, the new CEO of Teva Pharmaceutical Industries, is making good on his promise to launch a major restructuring of the indebted generic-drug giant. Schultz aims to reduce Teva’s costs around the globe by $3 billion by 2019. To do that, Teva will slash 25% of its workforce, about 14,000 employees, and shutter many of its R&D facilities, manufacturing plants, and offices worldwide next year. The Israeli firm’s stock spiked 16% upon the news.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society